230 related articles for article (PubMed ID: 23410901)
1. Successful EGFR-TKI rechallenge of leptomeningeal carcinomatosis after gefitinib-induced interstitial lung disease.
Nakamichi S; Kubota K; Horinouchi H; Kanda S; Fujiwara Y; Nokihara H; Yamamoto N; Tamura T
Jpn J Clin Oncol; 2013 Apr; 43(4):422-5. PubMed ID: 23410901
[TBL] [Abstract][Full Text] [Related]
2. Successful erlotinib rechallenge for leptomeningeal metastases of lung adenocarcinoma after erlotinib-induced interstitial lung disease: a case report and review of the literature.
Togashi Y; Masago K; Hamatani Y; Sakamori Y; Nagai H; Kim YH; Mishima M
Lung Cancer; 2012 Aug; 77(2):464-8. PubMed ID: 22579408
[TBL] [Abstract][Full Text] [Related]
3. Successful treatment with erlotinib after gefitinib-induced interstitial lung disease: a case report and literature review.
Koma Y; Matsuoka H; Yoshimatsu H; Suzuki Y
Int J Clin Pharmacol Ther; 2012 Oct; 50(10):760-4. PubMed ID: 22853866
[TBL] [Abstract][Full Text] [Related]
4. Erlotinib efficacy and cerebrospinal fluid concentration in patients with lung adenocarcinoma developing leptomeningeal metastases during gefitinib therapy.
Masuda T; Hattori N; Hamada A; Iwamoto H; Ohshimo S; Kanehara M; Ishikawa N; Fujitaka K; Haruta Y; Murai H; Kohno N
Cancer Chemother Pharmacol; 2011 Jun; 67(6):1465-9. PubMed ID: 21274533
[TBL] [Abstract][Full Text] [Related]
5. Promising Effects of Afatinib on Leptomeningeal Carcinomatosis Derived from Erlotinib-resistant Lung Adenocarcinoma.
Sekine A; Kato T; Iwasawa T; Baba T; Suido A; Sakuranaka H; Futaki M; Ogura T
Intern Med; 2016; 55(17):2457-61. PubMed ID: 27580550
[TBL] [Abstract][Full Text] [Related]
6. Erlotinib versus gefitinib for control of leptomeningeal carcinomatosis in non-small-cell lung cancer.
Lee E; Keam B; Kim DW; Kim TM; Lee SH; Chung DH; Heo DS
J Thorac Oncol; 2013 Aug; 8(8):1069-74. PubMed ID: 23804027
[TBL] [Abstract][Full Text] [Related]
7. [A case of lung adenocarcinoma with coexisting G719X and T790M EGFR mutations in which erlotinib was effective for the treatment of leptomeningeal carcinomatosis].
Katono K; Kasajima M; Ishihara M; Hayashi N; Nagashima Y; Igawa S; Masuda N
Gan To Kagaku Ryoho; 2013 Mar; 40(3):375-7. PubMed ID: 23507602
[TBL] [Abstract][Full Text] [Related]
8. Gefitinib successfully administered in a lung cancer patient with leptomeningeal carcinomatosis after erlotinib-induced pneumatosis intestinalis.
Uruga H; Moriguchi S; Takahashi Y; Ogawa K; Murase K; Mochizuki S; Hanada S; Takaya H; Miyamoto A; Morokawa N; Kishi K
BMC Cancer; 2018 Aug; 18(1):825. PubMed ID: 30115025
[TBL] [Abstract][Full Text] [Related]
9. Erlotinib in combination with pemetrexed/cisplatin for leptomeningeal metastases and cerebrospinal fluid drug concentrations in lung adenocarcinoma patients after gefitinib faliure.
Yang H; Yang X; Zhang Y; Liu X; Deng Q; Zhao M; Xu X; He J
Target Oncol; 2015 Mar; 10(1):135-40. PubMed ID: 24985049
[TBL] [Abstract][Full Text] [Related]
10. Retrospective analysis of survival in patients with leptomeningeal carcinomatosis from lung adenocarcinoma treated with erlotinib and gefitinib.
Kashima J; Okuma Y; Miwa M; Hosomi Y
Jpn J Clin Oncol; 2017 Apr; 47(4):357-362. PubMed ID: 28064206
[TBL] [Abstract][Full Text] [Related]
11. Successful rechallenge with erlotinib in a patient with EGFR-mutant lung adenocarcinoma who developed gefitinib-related interstitial lung disease.
Fukui T; Otani S; Hataishi R; Jiang SX; Nishii Y; Igawa S; Mitsufuji H; Kubota M; Katagiri M; Masuda N
Cancer Chemother Pharmacol; 2010 Mar; 65(4):803-6. PubMed ID: 20035424
[TBL] [Abstract][Full Text] [Related]
12. [Satisfactory outcome with erlotinib after failure with gefitinib in a patient with meningeal carcinomatosis secondary to non-small cell lung cancer].
Fujikura Y; Morishima Y; Ota K; Otsuka S; Homma S; Kurishima K; Hizawa N
Nihon Kokyuki Gakkai Zasshi; 2010 May; 48(5):391-6. PubMed ID: 20560443
[TBL] [Abstract][Full Text] [Related]
13. Interstitial lung disease following erlotinib (Tarceva) in a patient who previously tolerated gefitinib (Iressa).
Tammaro KA; Baldwin PD; Lundberg AS
J Oncol Pharm Pract; 2005 Sep; 11(3):127-30. PubMed ID: 16390601
[TBL] [Abstract][Full Text] [Related]
14. Erlotinib for pretreated squamous cell carcinoma of the lung in Japanese patients.
Hata A; Katakami N; Kunimasa K; Yoshioka H; Fujita S; Kaji R; Tachikawa R; Tomii K; Imai Y; Iwasaku M; Ishida T
Jpn J Clin Oncol; 2011 Dec; 41(12):1366-72. PubMed ID: 22058419
[TBL] [Abstract][Full Text] [Related]
15. Activity of pemetrexed and high-dose gefitinib in an EGFR-mutated lung adenocarcinoma with brain and leptomeningeal metastasis after response to gefitinib.
Yuan Y; Tan C; Li M; Shen H; Fang X; Hu Y; Ma S
World J Surg Oncol; 2012 Nov; 10():235. PubMed ID: 23134665
[TBL] [Abstract][Full Text] [Related]
16. High-dose, pulsatile erlotinib in two NSCLC patients with leptomeningeal metastases--one with a remarkable thoracic response as well.
Kuiper JL; Smit EF
Lung Cancer; 2013 Apr; 80(1):102-5. PubMed ID: 23375403
[TBL] [Abstract][Full Text] [Related]
17. Randomized phase II study of gefitinib versus erlotinib in patients with advanced non-small cell lung cancer who failed previous chemotherapy.
Kim ST; Uhm JE; Lee J; Sun JM; Sohn I; Kim SW; Jung SH; Park YH; Ahn JS; Park K; Ahn MJ
Lung Cancer; 2012 Jan; 75(1):82-8. PubMed ID: 21684626
[TBL] [Abstract][Full Text] [Related]
18. Clinical Efficacy of Afatinib Treatment for a Patient with Leptomeningeal Carcinomatosis.
Kawaguchi Y; Hanaoka J; Hayashi H; Mizusaki N; Iihara H; Itoh Y; Sugiyama T
Chemotherapy; 2017; 62(3):147-150. PubMed ID: 28030859
[TBL] [Abstract][Full Text] [Related]
19. Epidermal growth factor receptor tyrosine kinase inhibitors as a first-line therapy for never-smokers with adenocarcinoma of the lung having asymptomatic synchronous brain metastasis.
Kim JE; Lee DH; Choi Y; Yoon DH; Kim SW; Suh C; Lee JS
Lung Cancer; 2009 Sep; 65(3):351-4. PubMed ID: 19157632
[TBL] [Abstract][Full Text] [Related]
20. EGFR-TKI and lung adenocarcinoma with CNS relapse: interest of molecular follow-up.
Ruppert AM; Beau-Faller M; Neuville A; Guerin E; Voegeli AC; Mennecier B; Legrain M; Molard A; Jeung MY; Gaub MP; Oudet P; Quoix E
Eur Respir J; 2009 Feb; 33(2):436-40. PubMed ID: 19181917
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]